a Department of Pharmaceutics and Biopharmaceutics , Kiel University , Kiel , Germany.
Expert Opin Drug Deliv. 2019 Jan;16(1):59-68. doi: 10.1080/17425247.2019.1553955. Epub 2018 Dec 4.
Nanoparticles are under discussion in drug delivery for more than 20 years now, but examples for nanoparticulate formulations in the treatment of respiratory diseases are rare and mostly limited to the administration of sub-micron drug particles (ultrafine particles). However, nanoparticles may also carry specific benefits for respiratory treatment. Are nanoparticles the next-generation drug carrier system to facilitate systemic delivery, sustained release and cancer treatment in the lungs?
This review will look into the promises and opportunities of the use of nanoparticles in the treatment of respiratory diseases. Important aspects to discuss are the fate of nanoparticles in the lung and mechanisms for reproducible delivery of nanoparticulate formulations to the lungs. Examples are given where nanoparticles may be advantageous over for traditional formulations and further aspects to explore are mentioned.
The benefit of nanoparticulate systems for respiratory delivery adds to the portfolio of possible formulation strategies, depends on the intended functionality and needs more exploration. Advantages of such systems are only seen in special cases.
纳米粒子在药物输送方面已经讨论了 20 多年，但在治疗呼吸系统疾病的纳米粒子制剂方面的例子很少，而且大多局限于亚微米药物颗粒（超细颗粒）的给药。然而，纳米粒子也可能为呼吸系统治疗带来特殊的益处。纳米粒子是否是下一代药物载体系统，可促进肺部的全身给药、缓释和癌症治疗？
本综述将探讨在治疗呼吸系统疾病中使用纳米粒子的前景和机遇。需要讨论的重要方面是纳米粒子在肺部的命运以及可重复地将纳米粒子制剂递送到肺部的机制。举例说明了纳米粒子在某些情况下可能优于传统制剂的优势，并提到了进一步需要探索的方面。
纳米粒子系统在呼吸传递方面的优势增加了可能的制剂策略组合，这取决于预期的功能，需要更多的探索。只有在特殊情况下才能看到此类系统的优势。
